Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04702035
Other study ID # NPH wearables
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 1, 2018
Est. completion date April 25, 2024

Study information

Verified date April 2024
Source University of Zurich
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

20 patients who are diagnosed with NPH receive a set of 5 wearable gyroscopes (IMUs, ZurichMove sensors) for a period of 3 days for measurement and characterization of their walking in an ambulatory setting. At a follow-up 2 weeks to 6 months after CSF diversion surgery, the examination is repeated and improvement is measured. The data will be compared with a healthy group of 20 age- and gender-matched individuals as well a a group of 20 young individuals.


Description:

Temporary attachment of IMUs to wrists and ankles of the patients and probands for a period of three days and recording of movement during a 10 meter-walking test, 180° turnaround and during normal movement at home. Group 1 (patients): Patients with a completed diagnostic concerning iNPH, who are planned to receive a VP-shunt by their responsible neurosurgeon (independently from the study), will be included. Before the shunt implantation, the patients will be examined at the USZ using wearable gyroscopes (like wristwatches) at both wrists and ankles as well as one around the body center. The short examination will comprise a patient history (MoCa test, Kiefer-score, Stein- and Langfitt-Score), a short examination (4 minute walking test, 180° turnaround) in hospital. Afterwards, the patient goes home, where the gyroscopes examine walking patterns for a period of three days. After this period, the patient brings the devices back to the hospital. The surgery will take place afterwards, independently from the study, as well as adjustments of the shunt's flow-resistance for achievement of optimal response to the therapy. After this optimal result is achieved, but latest after 6 months, the examination will be repeated. Groups 2 and 3 (controls): As well 20 subjects matched for sex and age with the patient's group as 20 healthy young subjects will be examined just like the patients preoperatively. Walking patterns shall be compared to identify changes between pre- and postoperatively as well as differences between patients and controls.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 25, 2024
Est. primary completion date April 25, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 100 Years
Eligibility Age limits for the NPH patient group and the matched healthy vonunteers group are 60-100 years. Age limits for the young healthy volunteers group are 18-40 years. Inclusion Criteria: NPH patient group: 1. Informed Consent as documented by signature prior to any study related procedures or informed consent by a legal representative in case of cognitive deficits. 2. Male and female patients alike 3. Age between 60 and 100 years 4. Clinical suspect for NPH 5. Significant improvement (by more than 10%) in walking speed or endurance in a standardized CSF-TAP test (of at least 35 ml CSF). 6. Planned implantation of a VP shunt for NPH treatment (independently from the study). Matched controls group: 1. Informed Consent as documented by signature prior to any study related procedures 2. Male and female patients alike (matched to group 1) 3. Age between 60 and 100 years (matched to group 1) 4. No clinical suspect for NPH or any other movement disorder Young controls group: 1. Informed Consent as documented by signature prior to any study related procedures 2. Male and female patients alike (matched to group 1) 3. Age between 18 and 40 years 4. No clinical suspect for NPH or any other movement disorder Exclusion Criteria: 1. Enrolment of the investigator, his/her family members, employees and other dependent persons (only for patients; no exclusion criteria for controls), 2. Apparent or suspected movement disorder or other known disorder, which might affect normal standing or walking 3. Cardiovascular disorders, which might affect physical resilience 4. Pregnant women 5. Pre-menopausal state of female patients and probands in groups 1 and 2. 6. Children and adolescents

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.

Locations

Country Name City State
Switzerland Dept. of Neurosurgery, Zurich University Hospital Zurich

Sponsors (2)

Lead Sponsor Collaborator
University of Zurich ETH Zurich

Country where clinical trial is conducted

Switzerland, 

References & Publications (1)

Renggli D, Graf C, Tachatos N, Singh N, Meboldt M, Taylor WR, Stieglitz L, Schmid Daners M. Wearable Inertial Measurement Units for Assessing Gait in Real-World Environments. Front Physiol. 2020 Feb 20;11:90. doi: 10.3389/fphys.2020.00090. eCollection 2020. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Walking characteristics Complex walking pattern comprising of stride length, width, frequency (altogether one parameter) Between 2 weeks to 6 months after CSF diversion surgery
Secondary 4 minutes timed Walk test Standard test (seconds) immediately after fixation of IMUs
Secondary 180 degree turnaround test Participants are asked to turn by 180 degrees. Steps needed are counted. immediately after fixation of IMUs
Secondary Kiefer score Standard score for iNPH severity, only patient group; range 0-26; higher indicates higher severity before surgery
Secondary Kiefer score Standard score for iNPH severity, only patient group; range 0-26; higher indicates higher severity after surgery (range 2 weeks to 6 months)
Secondary Stein and Langfitt score Standard score for patient independence, only patient group; range 0-IV; higher indicates higher dependency before surgery
Secondary Stein and Langfitt score Standard score for patient independence, only patient group; range 0-IV; higher indicates higher dependency after surgery (range 2 weeks to 6 months)
Secondary NPH recovery rate Standard rate for success of CSF diversion treatment in NPH. Calculated as follows: (Kiefer score preoperatively - Kiefer score postoperatively) / Kiefer score preoperatively x 10; range 0-10; Higher indicates better response to surgery after surgery (range 2 weeks to 6 months)
Secondary Evan´s Index Standard descriptor for width of lateral ventricles in iNPH. Calculated as maximum with of frontal horns / maximal diameter of brain in axial CT or MRI at the level of cella media; range: 0-1; higher indicates larger ventricles and more severe hydrocephlaus before surgery
Secondary Disproportionally Enlarged Subarachnoidal space Hydrocephalus (DESH) sign Positivity of standard sign in preoperative CT or MRI imaging, hinting at presence of iNPH. Values: Positive/Negative before surgery
Secondary Time from appearance of first symptoms to surgery From first appearance of symptoms to surgery in years before surgery
Secondary 3-dimensional characterization of walking patterns Detailed analysis of walking patterns recorded during the measurement phases by the wearable IMUs. before surgery
Secondary 3-dimensional characterization of walking patterns Detailed analysis of walking patterns recorded during the measurement phases by the wearable IMUs. after surgery (range 2 weeks to 6 months)
See also
  Status Clinical Trial Phase
Completed NCT03350750 - A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial N/A
Recruiting NCT05081128 - Efficacy in iNPH Shunting (PENS) Trial N/A
Recruiting NCT04975269 - Acetazolamide Trial in Normal Pressure Hydrocephalus Phase 2
Completed NCT05204745 - Ventriculomegaly and Gait Disturbance in the Senior Population in the Region of Västerbotten